Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCAT2 | O15382 | 1/20 | 0.65 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | GAA | P10253 | 1/20 | 0.57 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.57 |
| ▸ | SRC | P12931 | 1/20 | 0.57 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.57 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.57 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 6/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.54 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.54 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.53 |
| ▸ | TUBB | P07437 | 1/20 | 0.53 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.53 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.53 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.53 |
| ▸ | TUBB4B | P68371 | 1/20 | 0.53 |
| ▸ | TUBB3 | Q13509 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29011848 | 0.86 | GAA (0.60) | POLBGAAFGFR1SRCFGFR2 | |
| SCHEMBL30045516 | 0.86 | GAA (0.60) | POLBGAAFGFR1SRCFGFR2 | |
| SCHEMBL27779618 | 0.85 | HDAC4 (0.58) | BCAT2POLBGAAFGFR1SRC | |
| SCHEMBL5878337 | 0.85 | BCAT2 (0.87) | BCAT2PARP1SMN1; SMN2KDM4EMEN1 | |
| SCHEMBL28187515 | 0.85 | BCAT2 (0.58) | BCAT2POLBGAAFGFR1SRC | |
| SCHEMBL1515687 | 0.84 | GAA (0.63) | POLBGAAFGFR1SRCFGFR2 | |
| SCHEMBL269580 | 0.84 | SMN1; SMN2 (0.70) | POLBGAASMN1; SMN2HDAC4HDAC2 | |
| SCHEMBL30582476 | 0.83 | BCAT2 (0.83) | BCAT2SMN1; SMN2KDM4EMEN1KMT2A | |
| SCHEMBL1180921 | 0.83 | ABL1 (0.51) | BCAT2POLBGAAFGFR1SRC | |
| SCHEMBL6276231 | 0.83 | SLC6A3 (0.71) | POLBGAASMN1; SMN2HDAC4HDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2003047572-A1 | USE OF 1-PHENYL-OXAZOLIDINE-2-ONE COMPOUNDS AS PROTEASE M INHIBITORS | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | claimed |
| EP-1100505-A1 | A PHARMACEUTICAL COMBINATION COMPRISING A COX-2 INHIBITOR AND A iNOS INHIBITOR | AstraZeneca AB (SE) | 2001-05-23 | — | — | EP | claimed |
| WO-2000000200-A1 | A PHARMACEUTICAL COMBINATION COMPRISING A COX-2 INHIBITOR AND A iNOS INHIBITOR | ASTRAZENECA AB (SE) | 2000-01-06 | — | — | WO | claimed |
| WO-2025109097-A2 | NOVEL NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE INHIBITORS AND USES THEREOF | HEIDELBERG PHARMA RESEARCH GMBH (DE) | 2025-05-30 | — | — | WO | disclosed |
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-04-25 | — | — | US | disclosed |
| CN-115057794-B | Method for removing methylation of cerium catalytic oxidation amide by visible light induction | 桂林理工大学 | 2023-11-17 | — | — | CN | disclosed |
| CN-115057794-A | Novel method for removing methylation of cerium-induced catalytic oxidation amide by visible light | 桂林理工大学 | 2022-09-16 | — | — | CN | disclosed |
| WO-2019174279-A1 | 1,2-BENZISOSELENAZOL-3(2H)-ONE AND 1,2-BENZISOTHIAZOL-3(2H)-ONE DERIVATIVES AS BETA-LACTAM ANTIBIOTIC ADJUVANTS | THE HONG KONG POLYTECHNIC UNIVERSITY (CN) | 2019-09-19 | — | — | WO | disclosed |
| CN-109457268-A | A kind of method of electro-catalysis benzamide compound synthesis benzoxazoles | 福建医科大学 | 2019-03-12 | — | — | CN | disclosed |
| CN-109369555-A | A kind of method of microwave radiation benzamide compound synthesis benzoxazoles in water phase | 福建医科大学 | 2019-02-22 | — | — | CN | disclosed |
| CN-107734969-A | Molecules having pesticidal utility, and intermediates, compositions and methods related thereto | 美国陶氏益农公司 | 2018-02-23 | — | — | CN | disclosed |
| WO-2015074123-A1 | FUNCTIONALISED AND SUBSTITUTED INDOLES AS ANTI-CANCER AGENTS | Novogen ltd (AU) | 2015-05-28 | — | — | WO | disclosed |
| EP-1954670-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX Inc. (US) | 2008-08-13 | — | — | EP | disclosed |
| WO-2007062230-A2 | NUCLEAR RECEPTOR BINDING AGENTS | GTX, INC. (US) | 2007-05-31 | — | — | WO | disclosed |
| US-6780883-B2 | ANTICHOLESTEROL AGENTS; CARDIOVASCULAR DISORDERS; ANTILIPEMIC AGENTS; RESTENOSIS; DIETETICS | WARNER-LAMBERT COMPANY | 2004-08-24 | — | — | US | disclosed |
| WO-2003047572-A1 | USE OF 1-PHENYL-OXAZOLIDINE-2-ONE COMPOUNDS AS PROTEASE M INHIBITORS | MERCK PATENT GMBH (DE) | 2003-06-12 | — | — | WO | disclosed |
| CN-1335849-A | Pyrrolopyrimidines as protein kinase inhibitors | BASF AG (DE) | 2002-02-13 | — | — | CN | disclosed |
| EP-0127762-B1 | CONSTRAINED N-ALKYLAMINO ARYL KETONES AS SENSITIZERS FOR PHOTOPOLYMER COMPOSITIONS | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1987-07-22 | — | — | EP | disclosed |
| US-4535052-A | HIGH SPEED PHOTORESISTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1985-08-13 | — | — | US | disclosed |
| EP-0127762-A1 | Constrained N-alkylamino aryl ketones as sensitizers for photopolymer compositions | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1984-12-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132431-A1 | METHOD FOR ALKYLATING ACIDIC FUNCTIONAL GROUP | MGMT, MCL1, FANCF | BCAT2 456/4885POLB 232/4885GAA 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.